Boehringer Ingelheim announced its acquisition of AMAL Therapeutics, a private Swiss biotechnology company focused on cancer immunotherapy and advancing first-in-class therapeutic cancer vaccines derived from its technology platform, KISIMA.
AMAL’s lead vaccine, ATP128, is currently developed for stage IV colorectal cancer and is slated to begin first-in-human trials later this month.
The acquisition, along with that of the 2018 acquisition of Vira Therapeutics and in-license of OSE Immunotherapeutics’ SIRP-alpha targeting antibody, significantly enhances Boehringer Ingelheim’s strategic focus on immune cell-directed therapies..
The total buy could amount up to EUR 325 million (U.S. $366M) and is comprised of an upfront payment as well as contingent clinical, development and regulatory milestones plus up to EUR 100 million if certain commercial milestones are hit.
Read the press release
Don't miss your Daily Dose. Sign up to get news like this delivered right to your inbox.